Clinical Trial Update: Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir [Phase 3]

View source ↗

Summary

A Phase 3 trial assessing switch from protease inhibitor/ritonavir to a generic single-tablet regimen of tenofovir alafenamide/emtricitabine/dolutegravir in peo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• tenofovir alafenamide/emtricitabine/dolutegravir (single-tablet regimen)

Snippet

Sponsor: The HIV Netherlands Australia Thailand Research Collaboration | Conditions: HIV | Phase 3 | Status: COMPLETED